Winners and Losers in CLL at American Society of Hematology

There was a wealth of new data in CLL at ASH but which companies or drugs were the winners and losers in New Orleans? Find out...

December 16, 2013

Pinning down potential new opportunities for IL–8 and 4–1BB

What is old is new again - a look at some forgotten oncology targets that are coming back in fashion

November 13, 2018

New developments in neoantigen vaccines

A look a progress on NeoVax in GBM, RNA vaccines and even a novel CAR T cell therapy with a difference.

October 8, 2018

Update on CAR T cell therapies at CICON18

Some key notes on CAR T cell therapy developments ahead of SITC18 and ASH18

October 3, 2018

CICON18 Day 1 Highlights

Highlights from the first day of #CICON18 in New York

October 1, 2018

Preview of CICON18 – Part 2

Our second preview of what to expect at CICON18 - top 10 poster abstracts

September 24, 2018

Preview of CICON18 – Part 1

Part 1 of our #CICON18 Previews - a look at 11 intriguing IO related studies

September 20, 2018

Targeting Natural Killer Cells in Cancer Immunotherapy

Can we address inhibitory factors that dampen NK cells to enhance the anti-cancer effect on tumours?

October 11, 2017

Immunotherapy Possibilities in Pancreatic Cancer

A look at what's different about exceptional responders in PDAC and what can we learn about neoantigen approaches here?

October 5, 2017

The Future of Cancer Vaccines Part 5 – An Interview with Prof George Coukos

A look at the latest developments in cancer immunotherapy in ovarian cancer, with a particular focus on neoepitopes and cancer vaccines.

October 3, 2017

The Future of Cancer Vaccines Part 4 – An Interview with Prof Kees Melief

Interview with Prof Kees Melief, CSO ISA Immune System Activation Pharmaceuticals

October 2, 2017

The Future of Cancer Vaccines Part 3 – Interview with Prof Ugur Sahin

A look at Ugur Sahin's BioNTech and personalized mRNA vaccines

September 28, 2017

The Future of Cancer Vaccines Part 2 – interview with Dr Ira Mellman

Genentech have several cancer vaccine collaborations in place, where do they see the future going in this niche?

September 27, 2017

The Future of Cancer Vaccines – An Interview with Dr Cathy Wu

Part 1 of a new mini-series on cancer vaccines. This one covers an update on Neon's neoantigen approach...

September 26, 2017

How to disrupt the CAR T cell therapy space

Is the CAR T cell therapy space ready for disruption? At least one researcher thinks so. What does this entail?

September 21, 2017

Can this novel combination overcome resistance to checkpoint blockade?

An early look at a new IO combination that may help overcome resistance to checkpoint therapy

September 14, 2017

Corvus moves fast to target tumor microenvironment and improve checkpoint responses

Corvus Pharmaceuticals accelerates development of A2A receptor antagonist CPI-444 that could improve checkpoint responses.

September 26, 2016